Prevention of post-menopausal bone loss with 1α-hydroxy vitamin D3 a three-year prospective study
- 26 Downloads
An open and controlled prospective study was used to assess the preventive efficiency of 1α-hydroxy vitamin D3 (1α (OH) Vit. D3) on post-menopausal vertebral bone loss. Of the 36 patients included in the study, 25 completed two years of treatment with 1 μg/day of 1α (OH) Vit. D3 and 500 mg of calcium. The vertebral bone mineral density measured by dual photon absorptiometry did not vary in the treated group, whereas it decreased significantly in the control group at the end of the 2 years. At two years, withdrawal of treatment led to a signficant bone loss, whereas bone mass remained stable in a subgroup of patients who underwent a third year of treatment with 1α (OH) Vit. D3. Overall, tolerance was satisfactory. However, urinary calcium increased significantly during treatment and one third of the patients developed hypercalciuria ≥7.5 mmoles/24 h. No variation in either serum calcium or creatinine levels was noted. These results indicate that 1α (OH) Vit. D3 could be useful in preventing post-menopausal bone loss provided it was complemented by regular monitoring of urinary calcium excretion.
Key wordsOsteoporosis Prevention 1α-Hydroxy Vitamin
Unable to display preview. Download preview PDF.
- 5.Caniggia, A., Nuti, R., Loré, F., Martini, G., Turchetti, V., Righi, G. Pathophysiological study in women with postmenopausal osteoporosis on long-term treatment with calcitriol. In: Osteoporosis: Physiological Basis, Assessment, and Treatment, Eds: DeLuca, H.F. Mazess, R.B. 1990, 201–212.Google Scholar
- 8.Eastell, R., Yergey, A.L., Vieira, N.E., Cedel, S.L., Kumar, R., Riggs, B.L. Interrelationship among vitamin D metabolism, true calcium absorption, parathyroid function, and age in women: evidence of an age-related intestinal resistance to 1,25-Dihydroxyvitamin D action. J Bone Min Res 1991, 6, 125–132.CrossRefGoogle Scholar
- 13.Drezner, M.K., Nesbitt, T. Role of calcitriol in prevention of osteoporosis: Part I. Metabolism 1990, Suppl. 39, 180–23.Google Scholar
- 22.Lindholm, T.S., Nilsson, O.S., Kyhle, B.R., Elmstedt, E., Lindholm, T.C., Eriksson, S.A. Failures and complications in treatment of osteoporotic patients treated with 1α-hydroxyvitamin D3 supplemented by calcium. In: Osteoporosis, Eds.: Menczel J., et al. Chichester, John Wiley & Sons, 1982, 351–357.Google Scholar
- 24.Geusens, P., Dequeker, J. Long-term effect of nandrolone decanoate, 1α-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone Mineral 1986, 1, 347–357.PubMedGoogle Scholar
- 31.Ott, S.M., Chesnut, C.H. Tolerance to dose of calcitriol is associated with improved bone density in women with postmenopausal osteoporosis. J Bone Min Res 1990, Suppl. 2, S186.Google Scholar